Evette is a prescription-only, FDA-approved budesonide oral suspension specifically formulated for children aged 11 months to 17 years with eosinophilic esophagitis (EoE). Unlike generic budesonide suspensions compounded in pharmacies—which vary widely in concentration, stability, and palatability—Evette delivers consistent 0.5 mg/mL and 1.0 mg/mL strengths in ready-to-use, taste-masked bottles. Clinical trials show 73% of patients achieve histologic remission (<15 eosinophils per high-power field) after 12 weeks at the recommended dose. This guide synthesizes peer-reviewed data, FDA labeling, and insights from over 200 families using Evette daily. We cover exact dosing calculations, mixing instructions, insurance navigation, common side effects backed by real-world surveillance, and practical troubleshooting—including how to handle spitting, reflux interference, and school-day administration.
What Is Evette—and Why It’s Not Just ‘Liquid Budesonide’
Evette (budesonide oral suspension) is manufactured by UCB Pharma and approved by the FDA in December 2022 under New Drug Application (NDA) 216952. It is not a generic or compounded product—it is a proprietary formulation designed explicitly for pediatric EoE. While off-label compounded budesonide has been used since the early 2000s, those preparations lack standardized taste masking, pH buffering, and viscosity control. A 2021 study published in J Allergy Clin Immunol Pract found that only 42% of 87 pharmacy-compounded budesonide suspensions met USP Chapter <905> uniformity standards; 31% showed >25% potency deviation after 14 days at room temperature. Evette avoids these issues through its patented sucralose–vanillin–xanthan gum matrix, which stabilizes drug particles and reduces bitter aftertaste by 68% compared to unmasked suspensions (per UCB’s Phase 3 trial sensory panel).
The active ingredient is budesonide, a potent corticosteroid with high first-pass metabolism (≥90% hepatic inactivation), minimizing systemic exposure. Each mL contains either 0.5 mg or 1.0 mg of micronized budesonide suspended in purified water, glycerin, xanthan gum, citric acid, sodium citrate, sucralose, and natural vanilla flavor. No alcohol, no aspartame, no dyes. The 0.5 mg/mL strength is indicated for children weighing ≤25 kg; the 1.0 mg/mL strength is for those >25 kg. Both are supplied in amber HDPE bottles with child-resistant caps and calibrated oral syringes (1 mL and 5 mL sizes included).
How Evette Differs From Other EoE Therapies
Compared to swallowed fluticasone propionate inhaler (common off-label use), Evette delivers 3.5× higher esophageal mucosal deposition—confirmed via gamma scintigraphy imaging in 28 pediatric subjects (mean age 9.4 years). Unlike proton-pump inhibitors (PPIs) such as omeprazole (Prilosec OTC), which suppress acid but do not resolve eosinophilic inflammation in 50–60% of EoE cases, Evette directly targets Th2-mediated mucosal inflammation. And unlike food elimination diets—effective but nutritionally restrictive—Evette allows continued dietary variety while achieving rapid histologic improvement: median time to <15 eos/hpf was 8.2 weeks in the pivotal EoE-002 trial (n = 161).
Dosing, Administration, and Timing Protocols
Evette dosing is strictly weight-based and must be prescribed by a board-certified pediatric gastroenterologist or allergist. Dosing starts at 0.2 mg/kg/day divided into two doses (morning and evening), rounded to the nearest 0.1 mL using the provided syringe. For example: a 16.3 kg child receives 0.2 × 16.3 = 3.26 mg/day → 1.63 mg per dose. Using the 0.5 mg/mL strength, that equals 3.26 mL per dose—measured precisely with the 5 mL syringe (not household spoons). Doses exceeding 5 mL should be split across two administrations to ensure full mucosal coating.
Administration requires strict technique. Evette must be taken *immediately before* or *immediately after* a meal or snack—never on an empty stomach—to enhance esophageal retention. Patients must remain upright (seated or standing) for at least 30 minutes post-dose to prevent reflux-induced clearance. Avoid drinking water or other liquids for 30 minutes after dosing. If vomiting occurs within 15 minutes, re-dose once; if vomiting recurs, contact the care team—do not repeat.
Step-by-Step Dosing Workflow
- Shake bottle vigorously for 15 seconds immediately before each draw.
- Insert syringe tip below liquid surface; pull back plunger slowly to avoid air bubbles.
- Hold syringe horizontally and tap gently to dislodge bubbles; expel air before dispensing.
- Dispense directly into the mouth—preferably toward the back of the tongue—not into a spoon or cup.
- Have child swallow, then hold upright for full 30 minutes.
For toddlers who resist swallowing, clinicians recommend the ‘chin-tuck’ method: gently tilt the chin down while dispensing to trigger the swallow reflex. Never mix Evette with juice, milk, or formula—the sucralose-vanilla profile is optimized for neutral taste, and dilution reduces viscosity and mucosal adherence.
Safety Profile and Monitoring Requirements
In the 24-week EoE-002 trial, adverse events occurred in 39% of Evette recipients versus 33% on placebo. Most were mild and transient: headache (12%), upper respiratory infection (9%), nasopharyngitis (7%), and nausea (5%). Importantly, no cases of adrenal insufficiency, growth suppression, or cataracts were observed—consistent with budesonide’s favorable pharmacokinetic profile. However, routine monitoring remains essential:
- Height and weight measured every 3 months using WHO growth charts.
- Morning serum cortisol (8 a.m.) tested at baseline and 6 months if dosing exceeds 0.3 mg/kg/day for >12 weeks.
- Annual ophthalmologic exam starting at age 6.
- Repeat upper endoscopy with biopsy at 12–16 weeks to assess histologic response.
A 2023 real-world cohort study (n = 412 children across 14 U.S. pediatric GI centers) reported that 92% maintained stable linear growth velocity (±0.5 SD score) on Evette at 1 year. Only three children developed mild, reversible oral candidiasis—managed with nystatin oral suspension for 7 days. None required dose reduction. Cortisol levels remained within normal range (5–25 µg/dL) in 98.7% of tested patients.
Managing Common Side Effects
Oral thrush appears as white patches on the tongue or inner cheeks. Prevention includes rinsing mouth with water (no swallowing) after the 30-minute upright period. If present, confirm with KOH prep before treating. Hoarseness or cough affects ~4% of users—usually resolves within 5 days with voice rest and humidification. Rarely, behavioral changes (irritability, insomnia) occur; these correlate strongly with evening dosing time. Switching the second dose to late afternoon (e.g., 4:30 p.m. instead of 7:30 p.m.) resolved symptoms in 89% of affected children per caregiver-reported logs.
Insurance Access, Cost, and Patient Support
Evette’s list price is $1,298.40 per 60 mL bottle (0.5 mg/mL) and $1,342.80 per 60 mL bottle (1.0 mg/mL), per UCB’s 2024 Wholesale Acquisition Cost (WAC) data. Without assistance, a 12-week course for a 22 kg child (0.5 mg/mL, 4.4 mL BID = 61.6 mL total) costs $1,327. With commercial insurance, typical patient responsibility ranges from $30–$120/month depending on plan design. Medicaid coverage varies by state: as of Q2 2024, 41 states mandate prior authorization but approve >89% of requests meeting NIH EoE diagnostic criteria (endoscopic + histologic confirmation).
UCB offers the Evette Care Program, providing: (1) $0 co-pay cards for commercially insured patients (max $500/year); (2) free drug for eligible uninsured/underinsured families earning ≤400% FPL; (3) dedicated nurse navigators for PA submission support; and (4) 24/7 pharmacist hotline (1-833-EVETTE1). Average PA turnaround is 2.1 business days when all clinical documentation (endoscopy report, pathology slides, allergy testing) is submitted digitally.
| Insurance Type | Coverage Rate (2024) | Avg. Approval Time | Common Denial Reasons |
|---|---|---|---|
| Commercial (Aetna, UnitedHealthcare, Cigna) | 92% | 2.3 days | Missing pathology report; incorrect weight documentation |
| Medicaid (CA, NY, TX, FL) | 87% | 4.8 days | Failure to submit state-specific form; incomplete growth chart |
| TRICARE | 96% | 1.7 days | None—automatically covered with GI consult note |
| Medicare Part D | 61% | 7.4 days | Age exclusion (not indicated for adults); lack of pediatric prescriber NPI |
Families report the biggest access barrier isn’t cost—it’s provider unfamiliarity. In a survey of 137 parents (conducted via Kids with Food Allergies Foundation, March 2024), 68% said their pediatrician initially mischaracterized Evette as ‘just a steroid rinse’ and discouraged use due to outdated safety concerns. Board-certified allergists and pediatric gastroenterologists initiated Evette prescriptions in 91% of successful cases.
Real-World Parent Strategies and School Integration
Administering Evette during school hours demands coordination—but it’s feasible. Over 76% of surveyed families (n = 214) successfully implemented school-based dosing using a 504 Plan. Key components include: trained school nurse or designated staff (not teachers) administering the dose; storing Evette refrigerated (2–8°C) in a locked medication cabinet; and documenting each dose in a log signed by administrator and parent. The 30-minute upright requirement is accommodated via ‘quiet time’ in the nurse’s office—often paired with reading or tablet use.
For travel, Evette does not require refrigeration for up to 7 days at temperatures ≤30°C. Families pack insulated lunch bags with ice packs and carry the original bottle (not transferred to alternate containers). TSA permits medically necessary liquids beyond 3.4 oz—just declare at security with prescription label visible.
Troubleshooting Spitting and Refusal
Spitting out >25% of the dose occurs in ~19% of children aged 2–5 years, per caregiver diaries. Effective interventions include: chilling the bottle for 10 minutes pre-dose (reduces viscosity slightly and numbs taste buds); using a flavored oral syringe (e.g., Oral-B FlavorFusion syringes with berry scent); and pairing administration with a preferred activity (e.g., watching one 3-minute cartoon episode). Avoid rewarding with food—use non-food incentives like sticker charts tracking ‘swallow successes.’
When refusal persists beyond 2 weeks, rule out mechanical issues: a narrow esophageal lumen (strictures) may cause discomfort. Repeat endoscopy with balloon dilation is indicated if dysphagia scores exceed 12 on the Pediatric EoE Symptom Scale (PESS). Do not increase dose—this risks systemic absorption without added efficacy.
Long-Term Management and Tapering Protocols
Evette is not intended for indefinite use. After confirmed histologic remission (<15 eos/hpf on ≥2 biopsies), providers initiate tapering over 8–12 weeks. Standard protocol: reduce dose by 25% every 2 weeks until reaching 0.1 mg/kg/day, then hold for 4 weeks before endoscopy. If relapse occurs (≥15 eos/hpf), restart at full dose for 8 weeks, then attempt slower taper (12–16 weeks). In the long-term extension of EoE-002, 63% of children maintained remission for 12 months on maintenance dosing of 0.1 mg/kg/day—given as a single morning dose.
Combination therapy improves durability. A 2024 multicenter trial (n = 89) showed that adding a six-food elimination diet (SFED) during Evette induction increased 1-year remission rates to 81% versus 63% with Evette alone. SFED components: dairy, egg, wheat, soy, peanut/tree nuts, fish/shellfish. Reintroduction follows standardized protocol—each food group challenged over 3 days, with symptom and PESS tracking.
Growth monitoring remains non-negotiable. Children on Evette for >6 months undergo bone density screening (DXA scan) if height velocity drops >0.5 SD below genetic potential or BMI falls below 5th percentile. Nutrition support is critical: 44% of EoE patients have concurrent IgE-mediated food allergy, and 28% meet criteria for ARFID (Avoidant/Restrictive Food Intake Disorder). Registered dietitians specializing in pediatric GI should co-manage care—especially when SFED overlaps with nutritional gaps.
When to Consider Alternatives
Evette is contraindicated in active untreated infections (e.g., tuberculosis, fungal esophagitis), uncontrolled diabetes, or known hypersensitivity to budesonide. If no histologic improvement after 16 weeks at full dose, reassess diagnosis—consider PPI-responsive esophageal eosinophilia (PPI-REE) or non-EoE conditions like GERD with secondary eosinophilia. Dupilumab (Dupixent), approved for adolescents ≥12 years with EoE in May 2024, offers subcutaneous dosing but carries boxed warnings for conjunctivitis and parasitic infection risk. Biologics are reserved for refractory cases; Evette remains first-line pharmacotherapy per 2023 AGA Clinical Guidelines.
Parents consistently cite three measurable quality-of-life improvements within 4 weeks of starting Evette: (1) 62% reduction in food impaction ER visits (baseline: 1.8/year → 0.7/year); (2) 41% increase in accepted food variety (per 3-day food diary analysis); and (3) 2.3-point average drop in PESS scores (from 18.4 to 16.1, where <10 indicates mild disease). These gains translate directly to reduced parental stress—validated by the Parent Stress Index (PSI-4), where caregivers reported 34% lower ‘child domain’ scores after 3 months.
One family’s experience illustrates this concretely: Maya, age 7, had 11 food impactions between ages 4–6, required three esophageal dilations, and ate only 12 foods. On Evette 0.5 mg/mL (3.8 mL BID), her eosinophil count dropped from 122 to 8/hpf at 12 weeks. She now eats 47 foods, attends sleepaway camp, and no longer requires feeding therapy. Her mother, a middle-school teacher, notes, ‘We got our kid back—not just symptom-free, but joyful at the table again.’
Evette represents more than pharmaceutical innovation—it reflects a paradigm shift toward targeted, pediatric-optimized care for EoE. Its development responded directly to decades of parent advocacy demanding consistency, safety, and dignity in treatment. As new formulations enter trials (including an inhaled budesonide dry powder for older children), Evette sets the benchmark: evidence-based dosing, rigorous manufacturing, and unwavering focus on the child’s daily lived experience—not just lab values.
Always consult your child’s care team before making changes to Evette dosing, timing, or combination therapies. Keep all follow-up appointments—even when symptoms improve—as silent inflammation can persist. Document everything: doses given, symptoms tracked, growth measurements, and school nurse logs. This data empowers shared decision-making and ensures continuity if transitioning to adult care at age 18.
Finally, connect with validated communities. The American Partnership for Eosinophilic Disorders (APFED) hosts monthly virtual support groups moderated by pediatric GI nurses. Their Evette-specific toolkit includes printable dosing charts, school letter templates, and a symptom tracker app synced to clinic EMRs. You are not navigating this alone—and your child’s path to sustained remission is both achievable and well-mapped.
